SEC Filing Summary: BioSig Technologies, Inc.
Business Context and Reporting Period
This Form 8-K was filed by BioSig Technologies, Inc. (not Streamex Corp.) on November 3, 2016, reporting events occurring on October 28, 2016. The filing details a private placement of equity securities and the execution of related definitive agreements.
Key Financial Metrics and Transaction Details
- Capital Raised: $519,850 in aggregate consideration.
- Securities Issued: 346,567 Units sold to accredited investors.
- Unit Composition: Each Unit consists of one share of Common Stock and one warrant to purchase 0.5 shares of Common Stock.
- Warrant Terms: Initial exercise price of $1.50 per share; expiration date of October 28, 2019. Warrants are immediately exercisable.
- Use of Proceeds: Designated for general corporate purposes, growth initiatives, and capital expenditures. Proceeds are explicitly prohibited from being used for debt repayment, equity repurchases, or settling claims.
Material Changes and Agreements
The Company entered into a Unit Purchase Agreement, a Registration Rights Agreement, and ancillary documents. Key covenants include:
- Reporting Obligations: The Company must maintain registration under Section 12(b) or 12(g) of the Exchange Act and file all required reports until the warrants expire or investors no longer hold securities.
- Registration Rights: The Company agreed to file a registration statement within 45 days of closing to cover the resale of Investor Shares and warrant-issued shares. The statement must be declared effective within 120 days of filing.
- Liquidated Damages: Failure to meet registration timelines triggers liquidated damages of 1% of the purchase price per 30-day period of delinquency, capped at 6%. Unpaid damages accrue interest at 18% per annum.
Outlook, Risks, and Contingencies
The filing outlines specific risks related to the Company's ability to maintain its reporting status and register the securities for resale. If the Company fails to file or maintain the registration statement, it faces financial penalties. Additionally, the warrants include anti-dilution protections and provisions for fundamental transactions (change of control), ensuring investors receive equivalent consideration in such events. The filing does not provide forward-looking financial guidance or revenue projections.
Investor Verification Checklist
- Verify the Company's current compliance with Exchange Act reporting requirements (Section 12(b) or 12(g)).
- Confirm the status of the registration statement filing required within 45 days of the October 28, 2016 closing.
- Review the Company's capitalization table to assess the dilution impact of the 346,567 new shares and potential 173,284 warrant shares.
- Check for any subsequent filings regarding the use of the $519,850 proceeds to ensure adherence to the restricted use covenants.